COST-EFFECTIVENESS AND COST-UTILITY OF OLOPATADINE IN THE TREATMENT OF SEASONAL ALLERGIC CONJUNCTIVITIS (SAC) IN 6 EUROPEAN COUNTRIES

Author(s)

Lilliu H1, Smith AF2, Le Pen C1, Maurel F1, 1Clp-santé, Paris, France; 2Alcon Laboratories Ltd and Nuffield Laboratory of Ophthalmology, University of Oxford, Hemel Hempstead, Hertfordshire, United Kingdom

OBJECTIVES: To assess cost-effectiveness and cost-utility ratios of a new anti-allergic agent Olopatadine in comparison to the reference treatment, Levocabastine, in Seasonal Allergic Conjunctivitis (SAC) in France, Germany, Italy, Spain, Sweden and the United Kingdom. METHODS: Data from a randomized, double-blind clinical trial of Olopatadine (O) versus Levocabastine (L) in SAC were used in the analysis. A total of 210 patients were randomized (O:101, L:109). Ocular symptoms and investigator’s Clinical Global Impression (CGI) were reported at baseline and at days 7, 14, 30 and 42. Factorial analysis techniques were used to derive a synthetic symptoms score (effectiveness score) from multi-dimensional symptom scales. In order to transform symptoms scores into utility scores, a panel of 32 ophthalmologists was interviewed in the 6 European countries to collect data on the painfulness of various symptomatic statuses. Curves representing the evolution of effectiveness and utility scores over time were projected from 42 to 90 days, assuming 3 types of treatment effects after day 42, namely, a maintained effect (H1), a catch-up on comparitor (H2) and no additional effect (H3). Areas under effectiveness and utility curves (AUCs) were computed in both arms. Olopatadine-Levocabastine differentials were respectively represented in the effectiveness criterion as the number of Symptoms Adjusted Days saved, (SAD) and in the utility criterion as the number of Quality Adjusted Days saved, (QAD). RESULTS: Olopatadine showed a gain from 1.3 (H3) to 2.3 (H1) SADs, and from 0.8 (H3, UK) to 4.2 (H1, Germany) QADs, over 3 months. Assuming a 20% higher price for Olopatadine compared to Levocabastine, the incremental cost-effectiveness ratios of Olopatadine ranged from €1.27 (H1, France) to €21.3 (H3, Italy) per SAD saved, while incremental cost-utility ratio ranged from €1.06 to €23.4 per QAD saved. CONCLUSION: Olopatadine showed reasonable cost-effectiveness and cost-utility ratios versus Levocabastine in the treatment of SAC for 6 European countries.

Conference/Value in Health Info

2002-11, ISPOR Europe 2002, Rotterdam, The Netherlands

Value in Health, Vol. 5, No. 6 (November/December 2002)

Code

PES9

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Respiratory-Related Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×